Abstract
Introduction: Atezolizumab plus bevacizumab (AteBev) combination treatment is widely used as first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC). We aimed to clarify therapeutic issues regarding serum cytokines and the immune reaction in patients with uHCC treated with AteBev. Methods: We analyzed preserved serum from a previous prospective study on adult Japanese patients with chronic liver disease and uHCC who received AteBev treatment at our hospital. In that study, AteBev was administered intravenously every 3 weeks, and blood samples were collected before and after 3 weeks’ treatment. Dynamic computed tomography was performed after 6 weeks of treatment to assess response. Results: In the prospective study, 21 of the 59 patients showed partial response (PR) and 19 patients showed stable disease, but 19 patients showed progressive disease (PD). We found that serum levels of tumor necrosis factor-alpha, interleukin (IL)-6, and soluble IL-2 receptor (IL-2R) increased significantly in the PR group, but only soluble IL-2R increased significantly in the PD group. Regulatory T cells decreased significantly in the PD group, but there was no significant change in Th1 or Th2 cells from before to after treatment in any group. As regards soluble MHC-class I, pre-treatment levels were significantly lower in the PD group than in the PR group, and serum levels increased significantly with treatment in the PD group. Conclusion: These findings reveal a need to further improve T-cell priming and to further make T cells recognize tumor antigens in uHCC.
References
1.
Galle
PR
, Finn
RS
, Qin
S
, Ikeda
M
, Zhu
AX
, Kim
TY
, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
. Lancet Oncol
. 2021
;22
(7
):991
–1001
. .2.
Llovet
JM
, Villanueva
A
, Marrero
JA
, Schwartz
M
, Meyer
T
, Galle
PR
, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference
. Hepatology
. 2021
;73
(Suppl 1
):158
–91
. .3.
Fukumura
D
, Kloepper
J
, Amoozgar
Z
, Duda
DG
, Jain
RK
, Jain
RK
. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
. Nat Rev Clin Oncol
. 2018
;15
(5
):325
–40
. .4.
Chouaib
S
, Messai
Y
, Couve
S
, Escudier
B
, Hasmim
M
, Noman
MZ
. Hypoxia promotes tumor growth in linking angiogenesis to immune escape
. Front Immunol
. 2012
;3
:21
. .5.
Oyama
T
, Ran
S
, Ishida
T
, Nadaf
S
, Kerr
L
, Carbone
DP
, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells
. J Immunol
. 1998
;160
(3
):1224
–32
. .6.
Hegde
PS
, Wallin
JJ
, Mancao
C
. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
. Semin Cancer Biol
. 2018
;52
(Pt 2
):117
–24
. .7.
Gabrilovich
DI
, Chen
HL
, Girgis
KR
, Cunningham
HT
, Meny
GM
, Nadaf
S
, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
. Nat Med
. 1996
;2
(10
):1096
–103
. .8.
Goel
S
, Duda
DG
, Xu
L
, Munn
LL
, Boucher
Y
, Fukumura
D
, et al. Normalization of the vasculature for treatment of cancer and other diseases
. Physiol Rev
. 2011
;91
(3
):1071
–121
. .9.
Motz
GT
, Santoro
SP
, Wang
LP
, Garrabrant
T
, Lastra
RR
, Hagemann
IS
, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
. Nat Med
. 2014
;20
(6
):607
–15
. .10.
Hodi
FS
, Lawrence
D
, Lezcano
C
, Wu
X
, Zhou
J
, Sasada
T
, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma
. Cancer Immunol Res
. 2014
;2
(7
):632
–42
. .11.
Wallin
JJ
, Bendell
JC
, Funke
R
, Sznol
M
, Korski
K
, Jones
S
, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
. Nat Commun
. 2016
;7
:12624
. .12.
Gabrilovich
DI
, Nagaraj
S
. Myeloid-derived suppressor cells as regulators of the immune system
. Nat Rev Immunol
. 2009
;9
(3
):162
–74
. .13.
Roland
CL
, Lynn
KD
, Toombs
JE
, Dineen
SP
, Udugamasooriya
DG
, Brekken
RA
. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer
. PLoS One
. 2009
;4
(11
):e7669
. .14.
Facciabene
A
, Peng
X
, Hagemann
IS
, Balint
K
, Barchetti
A
, Wang
LP
, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells
. Nature
. 2011
;475
(7355
):226
–30
. .15.
Voron
T
, Colussi
O
, Marcheteau
E
, Pernot
S
, Nizard
M
, Pointet
AL
, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
. J Exp Med
. 2015
;212
(2
):139
–48
. .16.
Nagai
H
, Mukozu
T
, Matsui
D
, Kanekawa
T
, Kanayama
M
, Wakui
N
, et al. Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma
. Clin Dev Immunol
. 2012
;2012
:1
–8
. .17.
Nagai
H
, Mukozu
T
, Kobayashi
K
, Amanuma
M
, Yoshimine
N
, Ogino
Y
, et al. Influence of sorafenib on host immunity in patients with liver cirrhosis with advanced hepatocellular carcinoma stratified by etiology
. Anticancer Res
. 2019
;39
(4
):2183
–91
. .18.
Nagai
H
, Mukozu
T
, Kobayashi
K
, Nogami
A
, Nagumo
H
, Mohri
K
, et al. Lenvatinib might induce activation of host immunity in patients with hepatocellular carcinoma
. Oncology
. 2023
;101
(1
):32
–40
. .19.
Hayakawa
Y
, Tsuchiya
K
, Kurosaki
M
, Yasui
Y
, Kaneko
S
, Tanaka
Y
, et al. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
. Invest New Drugs
. 2022
;40
(2
):392
–402
. .20.
Kobayashi
K
, Nagai
H
, Matsui
T
, Matsuda
T
, Higai
K
. Importance of atezolizumab Plus bevacizumab combination treatment as first-line therapy for immunological changes in patients with unresectable hepatocellular carcinoma
. Anticancer Res
. 2023
;43
(10
):4601
–9
. .21.
Jung
T
, Schauer
U
, Heusser
C
, Neumann
C
, Rieger
C
. Detection of intracellular cytokines by flow cytometry
. J Immunol Methods
. 1993
;159
(1–2
):197
–207
. .22.
Llovet
JM
, Di Bisceglie
AM
, Bruix
J
, Kramer
BS
, Lencioni
R
, Zhu
AX
, et al. Design and endpoints of clinical trials in hepatocellular carcinoma
. J Natl Cancer Inst
. 2008
;100
(10
):698
–711
. .23.
Lencioni
R
, Llovet
JM
. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
. Semin Liver Dis
. 2010
;30
(1
):52
–60
. .24.
Takahashi
S
. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy
. Biol Pharm Bull
. 2011
;34
(12
):1785
–8
. .25.
Beutler
B
, Cerami
A
. Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response
. Endocr Rev
. 1988
;9
(1
):57
–66
. .26.
Tracey
KJ
, Vlassara
H
, Cerami
A
. Cachectin/tumor necrosis factor
. Lancet
. 1989
;1
:1122
–6
. .27.
Brockhaus
M
, Schoenfeld
HJ
, Schlaeger
EJ
, Hunziker
W
, Lesslauer
W
, Loetscher
H
. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies
. Proc Natl Acad Sci USA
. 1990
;87
(8
):3127
–31
. .28.
Hohmann
HP
, Remy
R
, Brockhaus
M
, van Loon
AP
. Two different cell types have different major receptors for human tumor necrosis factor (TNFα)
. J Biol Chem
. 1989
;264
(25
):14927
–34
. .29.
Schuett
H
, Luchtefeld
M
, Grothusen
C
, Grote
K
, Schieffer
B
. How much is too much? Interleukin-6 and its signalling in atherosclerosis
. Thromb Haemost
. 2009
;102
(2
):215
–22
. .30.
Rubin
LA
, Kurman
CC
, Fritz
ME
, Biddison
WE
, Boutin
B
, Yarchoan
R
, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro
. J Immunol
. 1985
;135
(5
):3172
–7
. .31.
Ormandy
LA
, Hillemann
T
, Wedemeyer
H
, Manns
MP
, Greten
TF
, Korangy
F
. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
. Cancer Res
. 2005
;65
(6
):2457
–64
. .32.
Yamaguchi
T
, Sakaguchi
S
. Regulatory T cells in immune surveillance and treatment of cancer
. Semin Cancer Biol
. 2006
;16
(2
):115
–23
. .33.
Gao
Q
, Qiu
SJ
, Fan
J
, Zhou
J
, Wang
XY
, Xiao
YS
, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection
. J Clin Oncol
. 2007
;25
(18
):2586
–93
. .34.
Zhou
SL
, Zhou
ZJ
, Hu
ZQ
, Huang
XW
, Wang
Z
, Chen
EB
, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib
. Gastroenterology
. 2016
;150
(7
):1646
–58.e17
. .35.
Finkelmeier
F
, Canli
Ö
, Tal
A
, Pleli
T
, Trojan
J
, Schmidt
M
, et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
. Eur J Cancer
. 2016
;59
:152
–9
. .36.
Orme
JJ
, Jazieh
KA
, Xie
T
, Harrington
S
, Liu
X
, Ball
M
, et al. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
. Oncoimmunology
. 2020
;9
(1
):1744980
. .37.
Neefjes
J
, Jongsma
ML
, Paul
P
, Bakke
O
. Towards a systems understanding of MHC class I and MHC class II antigen presentation
. Nat Rev Immunol
. 2011
;11
(12
):823
–36
. .38.
Chang
CC
, Campoli
M
, Ferrone
S
. HLA class I deffects in malignant lesions: what have we learned
. Keio J Med
. 2003
;52
(4
):220
–9
. .39.
Ferrara
N
, Gerber
HP
, LeCouter
J
. The biology of VEGF and its receptors
. Nat Med
. 2003
;9
(6
):669
–76
. .40.
Finn
RS
, Kudo
M
, Cheng
AL
, Wyrwicz
L
, Ngan
RKC
, Blanc
JF
, et al. Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study
. Clin Cancer Res
. 2021
;27
(17
):4848
–58
. .41.
Veenendaal
LM
, Jin
H
, Ran
S
, Cheung
L
, Navone
N
, Marks
JW
, et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors
. Proc Natl Acad Sci USA
. 2002
;99
(12
):7866
–71
. .© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
